This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, D.-W.
Right arrow Articles by Chen, S.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, D.-W.
Right arrow Articles by Chen, S.-L.

 Previous Article  |  Next Article 

Journal of Virology, March 2000, p. 2888-2894, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer

Dai-Wei Liu,1,2 Yeou-Ping Tsao,1,3 John T. Kung,4 Yu-An Ding,5 Huey-Kang Sytwu,1 Xiao Xiao,6 and Show-Li Chen1,*

Department of Microbiology and Immunology1 and the Graduate Institute of Medical Science,2 National Defense Medical Center, Institute of Molecular Biology, Academia Sinica,4 and Division of Cardiology, Veterans General Hospital,5 Taipei, and Department of Ophthalmology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan,3 Taiwan, Republic of China, and Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania6

Received 7 October 1999/Accepted 7 December 1999

In this study, we explore a potential vaccine for human papillomavirus (HPV)-induced tumors, using heat shock protein as an adjuvant, a peptide vaccine for safety, and adeno-associated virus (AAV) as a gene delivery vector. The tumor vaccine was devised by constructing a chimeric gene which contained HPV type 16 E7 cytotoxic T-lymphocyte (CTL) epitope DNA (M. C. Feltkamp, H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijfhout, J. ter Schegget, C. J. Melief, and W. M. Kast, Eur. J. Immunol. 23:2242-2249, 1993) fused with the heat shock protein gene as a tumor vaccine delivered via AAV. Our results demonstrate that this vaccine can eliminate tumor cells in syngeneic animals and induce CD4- and CD8-dependent CTL activity in vitro. Moreover, studies with knockout mice with distinct T-cell deficiencies confirm that CTL-induced tumor protection is CD4 and CD8 dependent. Taken together, the evidence indicates that this chimeric gene delivered by AAV has potential as a cervical cancer vaccine.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, Republic of China. Phone: 886-2-87923100, ext. 18543. Fax: 886-2-23687806. E-mail: yptsao{at}mail.ht.net.tw.

Journal of Virology, March 2000, p. 2888-2894, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., Muruve, D. A. (2008). Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors. J. Virol. 82: 2727-2740 [Abstract] [Full Text]  
  • Lin, J., Zhi, Y., Mays, L., Wilson, J. M. (2007). Vaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8+ T-Cell Responses in Mice. J. Virol. 81: 11840-11849 [Abstract] [Full Text]  
  • Bae, S. H., Park, Y.-J., Park, J.-B., Choi, Y. S., Kim, M. S., Sin, J.-I. (2007). Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy. Clin. Cancer Res. 13: 341-349 [Abstract] [Full Text]  
  • Wu, S., Meng, L., Wang, S., Wang, W., Xi, L., Tian, X., Chen, G., Wu, Y., Zhou, J., Xu, G., Lu, Y., Ma, D. (2006). Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA.. Clin. Cancer Res. 12: 2032-2037 [Abstract] [Full Text]  
  • Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., Kleinschmidt, J. A. (2006). Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1. J. Virol. 80: 2621-2630 [Abstract] [Full Text]  
  • Mahdavi, A., Monk, B. J. (2005). Vaccines Against Human Papillomavirus and Cervical Cancer: Promises and Challenges. The Oncologist 10: 528-538 [Abstract] [Full Text]  
  • Johnson, P. R., Schnepp, B. C., Connell, M. J., Rohne, D., Robinson, S., Krivulka, G. R., Lord, C. I., Zinn, R., Montefiori, D. C., Letvin, N. L., Clark, K. R. (2005). Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques. J. Virol. 79: 955-965 [Abstract] [Full Text]  
  • Rapp, U. K., Kaufmann, S. H. (2004). DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 16: 597-605 [Abstract] [Full Text]  
  • Palmer, G. A., Brogdon, J. L., Constant, S. L., Tattersall, P. (2004). A Nonproliferating Parvovirus Vaccine Vector Elicits Sustained, Protective Humoral Immunity following a Single Intravenous or Intranasal Inoculation. J. Virol. 78: 1101-1108 [Abstract] [Full Text]  
  • Devaraj, K., Gillison, M. L., Wu, T.-C. (2003). DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA. CROBM 14: 345-362 [Abstract] [Full Text]  
  • Kim, T.-Y., Myoung, H.-J., Kim, J.-H., Moon, I.-S., Kim, T.-G., Ahn, W.-S., Sin, J.-I. (2002). Both E7 and CpG-Oligodeoxynucleotide Are Required for Protective Immunity against Challenge with Human Papillomavirus 16 (E6/E7) Immortalized Tumor Cells: Involvement of CD4+ and CD8+ T Cells in Protection. Cancer Res. 62: 7234-7240 [Abstract] [Full Text]  
  • Sun, J.-Y., Krouse, R. S., Forman, S. J., Senitzer, D., Sniecinski, I., Chatterjee, S., Wong, K. K. Jr. (2002). Immunogenicity of a p210BCR-ABL Fusion Domain Candidate DNA Vaccine Targeted to Dendritic Cells by a Recombinant Adeno-associated Virus Vector in Vitro. Cancer Res. 62: 3175-3183 [Abstract] [Full Text]  
  • Kammerer, R., Stober, D., Riedl, P., Oehninger, C., Schirmbeck, R., Reimann, J. (2002). Noncovalent Association with Stress Protein Facilitates Cross-Priming of CD8+ T Cells to Tumor Cell Antigens by Dendritic Cells. J. Immunol. 168: 108-117 [Abstract] [Full Text]  
  • Ponnazhagan, S., Curiel, D. T., Shaw, D. R., Alvarez, R. D., Siegal, G. P. (2001). Adeno-associated Virus for Cancer Gene Therapy. Cancer Res. 61: 6313-6321 [Full Text]  
  • Sarukhan, A., Camugli, S., Gjata, B., von Boehmer, H., Danos, O., Jooss, K. (2001). Successful Interference with Cellular Immune Responses to Immunogenic Proteins Encoded by Recombinant Viral Vectors. J. Virol. 75: 269-277 [Abstract] [Full Text]  
  • Zheng, H., Palese, P., García-Sastre, A. (2000). Antitumor Properties of Influenza Virus Vectors. Cancer Res. 60: 6972-6976 [Abstract] [Full Text]  
  • Liu, D.-W., Tsao, Y.-P., Hsieh, C.-H., Hsieh, J.-T., Kung, J. T., Chiang, C.-L., Huang, S.-J., Chen, S.-L. (2000). Induction of CD8 T Cells by Vaccination with Recombinant Adenovirus Expressing Human Papillomavirus Type 16 E5 Gene Reduces Tumor Growth. J. Virol. 74: 9083-9089 [Abstract] [Full Text]  
  • Jooss, K., Gjata, B., Danos, O., von Boehmer, H., Sarukhan, A. (2001). Regulatory function of in vivo anergized CD4+ T cells. Proc. Natl. Acad. Sci. USA 98: 8738-8743 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»